MedTrace Logo

Clinical Study on Treatment of L-DOPA-Induced Dyskinesia With Tianqi Pingchan Granule Combined With Amantadine

NCT04173832 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-12-01

No results posted yet for this study

Summary

A randomized, double-blind, placebo-controlled, multi-center clinical trial was conducted to observe the improvement in the level of dyskinesia in patients with Parkinson's disease during the 12-week period of oral treatment with Tianqi Pingchan Granule Combined With Amantadine. To observe the differences of the safety and effectiveness between Tianqi Pingchan Granule combined with amantadine and placebo combined with amantadine.

Conditions

  • L-DOPA-Induced Dyskinesia

Interventions

DRUG

Tianqi Pingchan Granule Combined With Amantadine

Tianqi Pingchan Granule and Amantadine are given to patients simultaneously

DRUG

Placebo Combined With Amantadine

Placebo and Amantadine are given to patients simultaneously

Sponsors & Collaborators

  • Shanghai University of Traditional Chinese Medicine

    collaborator OTHER

  • Shanghai Municipal Hospital of Traditional Chinese Medicine

    collaborator OTHER

  • Wenzhou Central Hospital

    collaborator OTHER

  • The Affiliated Hospital of Qingdao University

    collaborator OTHER

  • Affiliated Hospital of Nanjing University of Chinese Medicine

    collaborator OTHER

  • The Affiliated Hospital of Xuzhou Medical University

    collaborator OTHER

  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2020-12-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04173832 on ClinicalTrials.gov